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Abstract – The authors characterized the clinical forms of multi-
ple sclerosis, discussed selected issues from epidemiology of the 
disease in the world, Europe and Poland. They drew attention to 
the importance of sex and age in the development of multiple 
sclerosis, stressing that the disease most often affects people aged 
20-40, which is the period of the greatest professional activity. 
The etiology of the disease is also discussed, with emphasis on 
the fact that it is caused by many factors, including autoimmune, 
environmental and genetic factors. 
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Streszczenie – Autorzy scharakteryzowali postacie kliniczne 
stwardnienia rozsianego,  omówili wybrane zagadnienia z epide-
miologii choroby w skali świata, Europy a także Polski. Zwrócili 
uwagę na znaczenie płci i wieku w rozwoju stwardnienia rozsia-
nego, podkreślając, że choroba najczęściej dotyczy osób w wieku 
20-40 lat, a więc w okresie największej aktywności zawodowej. 
Omówiono także etiologię choroby  wskazując, że powstaje ona 
pod wpływem wielu czynników,  w tym autoimmunologicznych, 
środowiskowych, genetycznych. 
 
Słowa kluczowe – stwardnienie rozsiane , klasyfikacja, epide-
miologia, etiologia. 
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I. INTRODUCTION 
 
ultiple sclerosis (MS), as a neurological, multiphase 
and progressive disease, has been known since the 
mid-sixteenth century. The case of the disease was 
described for the first time in the second half of the nine-
teenth century (1868). During the autopsy, small, hardened 
scars were found in the brain and in the spinal cord. It was 
the first recognition of multiple sclerosis as a separate dis-
ease entity. According to the aforementioned, MS has been 
identified and classified as sclerosis multiplex. In Poland, 
the disease was diagnosed only after the First World War 
[1,2,3]. 
 The MS disease, with its long-term process and progres-
sive decline, is contributing to lowering the quality of life. 
For centuries, philosophers have been trying to discover the 
most important goals of an individual, whose implementa-
tion was supposed to lead to a satisfying life. The begin-
nings of interest in quality of life date back to ancient 
times, when thinkers such as Aristotle or Hippocrates tried 
to find out what constitutes the foundation of a happy and 
satisfying life. For Hippocrates, a happy life is concretised 
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as a state of internal balance. For Aristotle, however, the 
highest goal to achieve was striving for the greatest good 
that would bring happiness. The concept of happiness 
means not only the objective state, but also the subjective 
feelings of the patient [4]. According to the World Health 
Organization, the concept of quality of life is defined as ‘an 
individual way of perceiving an individual's position in a 
cultural context and the system of values in which he lives, 
and in relation to tasks, expectations and standards deter-
mined by environmental conditions’. What is more, we can 
add social roles, group functioning, adaptability and psy-
chological well-being to the exponents of the quality of life 
[5,6]. 
 
I. MULTIPLE SCLEROSIS AND 
CLASSIFICATIONS 
 
Multiple sclerosis is one of the most common diseases of 
the central nervous system. This is an autoimmune disease 
with inflammatory-demyelinating foundation. MS is a de-
myelinating disease of the nervous system, in the course of 
which multifocal damage to the nervous tissue occurs. As a 
result of pathomechanisms, multifocal damage to the struc-
tures of the central nervous system (CNS) [1] arises. As the 
name suggests, the disease process favors the emergence of 
scattered foci, which in turn leads to numerous clinical 
symptoms [7]. The consequence of the disease process is a 
scattered CNS damage and occupation of periventricular 
structures, subcortical structures of the white matter of the 
hemisphere, brain stem, cerebellum and spinal cord. It is 
characterized by a variable, progressive and specific 
course. It systematically leads to deterioration of the pa-
tient's physical condition and leads to permanent disability 
[2]. The emergence of a chronic disease such as multiple 
sclerosis contributes to a significant disruption of current 
life. The disease process gradually weakens and limits the 
patient leading to physical and mental disability [2,3]. 
 As a consequence, MS affects the cognitive sphere, caus-
ing its disorder. It is difficult to predict the course of the 
disease itself, as it is individual depending on the patient. 
However, it may be helpful to know about the type of MS 
that the patient is suffering from. According to the classifi-
cation of Lublin and Reinhold, clinical types of multiple 
sclerosis may be distinguished [1,2,8]. 
 The first type of MS is a relapsing remitting form in 
which there are key features of the disease and a complete 
or partial return of functions that have been impaired. This 
type affects about 90% of all patients at the beginning of 
the course of the disease. Unexpected symptoms of damage 
to the nervous system are indicated. The notion of a relapse 
is understood as the occurrence of new symptoms or inten-
sification of objective, neurological focal symptoms, dura-
tion of which is not shorter than 24h. Relapses can be mild, 
for example, numbness of a specific area of the skin, or 
those that the person does not even know about. Relapses 
can also be sharper, for example, paresis of one limb. The 
intensification of harsher or milder symptoms persists at a 
stable level (plateau phase) up to several weeks. Typical 
symptoms of the attack are: ataxia, sphincter dysfunctions, 
sensory disturbances and spastic paresis. These symptoms 
may withdraw or partly remain. The relapses are interlaced 
with periods of relative stability which lasts for months and 
years, and its course may vary in each patient. The frequen-
cy of relapses varies with the progression of the disease. It 
is estimated that the highest attack rate is in the first and 
second year of the disease, and then it gradually decreases. 
[1,2,7,9,10] 
 Another type is secondary progressive, which affects 
about 80% of people struggling with relapsing-remitting 
type. The secondary progressive form appears after years of 
the disease and is a progression after the relapse and remis-
sion period. This type can appear at any moment in the 
patient's life. It is the most common variant in the later 
stages of the disease and leads to the greatest disability. 
After a period of many years, neurological symptoms add 
up to the progressive and irreversible disability of the pa-
tient. The primary progressive form reveals lesions from 
the beginning. This applies to people with late onset of the 
disease in case of which remission and even partial with-
drawal of symptoms is not noticed. Degeneration occurs 
gradually without clear exacerbations. [1,2,7,9-11] 
 Another type is the progressive relapsing type. This is 
the rarest form of MS, it is distinguished by progressive 
deterioration with episodes of exacerbations. It has also 
been mentioned about so-called pseudo-relapses or pseudo-
attacks, which are transitory and reversible neurological 
symptoms. Usually these are the symptoms that occurred in 
the projection of previous exacerbations and have been 
withdrawn. They may appear in the further parts of the 
course of the disease under the influence of external fac-
tors, such as a higher temperature in the form of bath, heat, 
or infection. They usually appear in the form of patients’ 
complaints about pain, reduced activity, physical exhaus-
tion or cognitive decline. The diagnosis of pseudo-relapses 
is important from the clinical point of view, because such 
patients should not be treated with steroids. [1,2,7,9-11] 
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III. EPIDEMIOLOGY AND ETIOLOGY 
 
SM in the world 
 
The characteristic part of the disease is its geographic 
distribution. An uneven occurrence of multiple sclerosis in 
various geographical regions is assumed. MS occurs mainly 
in the temperate zone, and the incidence of disease increas-
es with increasing latitude. This applies to the northern and 
southern hemisphere. For example, the number of cases of 
MS in the countries of the Mediterranean region, e.g. 
France, Spain, Italy equals about 50 patients per100,000 
inhabitants, while in Northern Europe, e.g. Great Britain, it 
reaches 100-112 per 100,000 inhabitants, up to Scotland 
(Aberdeen) 144 per 100,000 inhabitants. Today, it is em-
phasized that the differential diagnosis of MS in regions at 
the same latitude, e.g. 44 ° north latitude, in Akés (France), 
there are 9 cases per 100,000 inhabitants, in Copparo (Sar-
dinia) - 31 cases per 100,000 inhabitants, in Minnesota 
(USA) - 122 cases per 100,000 inhabitants. [12-15] 
 
SM in Poland 
 
 Our country belongs to the high risk zone with a morbid-
ity of 40-80 per 100,000 inhabitants, where the average rate 
in Europe equals 4.3 cases per 100,000 people. 
 In Poland, over 45 thousand people suffer from MS, 
while over 2.5 million people affected by the disease are 
estimated worldwide. The average incidence rate is 2.5 per 
100,000 people per year. In Poland, there are around 2 cas-
es of illness per 100,000 people per year. [2,3,16-18]. 
 
Sex and age 
 
 The disease affects almost twice as much women than 
men. There is no predilection for sex in the primary pro-
gressive form. The disease is rare for people over 50 years 
old (about 10% of all cases), as well as for children under 
16 years of age. If the disease develops in a child under the 
age of 16, it is referred to as a pediatric form of multiple 
sclerosis, whereas in a person over 50 – a late form of mul-
tiple sclerosis. Most often, the disease affects people aged 
20-40, that is in the period of the highest professional activ-
ity. [12,13,14,15,19-22] 
 
Etiology 
 
Outlined epidemiological differences may be related to  
the ethnic origin of the studied population, but also to ex-
ternal factors. This may be indicated by research conducted 
by emigrants in Israel and South Africa. They showed that 
people emigrating from the ‘high risk’ zones to the ‘low 
risk’ zones maintain an increased risk of becoming ill when 
they emigrate in adulthood, whereas if emigration occurs at 
a younger age, immigrants are subject to the risk character-
istic for the country they came to, thereby less risk of get-
ting sick. While adults emigrating from the country of a 
‘low risk of disease’ to a country with a  ‘high risk of dis-
ease’ they still have a low risk of falling ill, while children 
with this direction of emigration are at a high risk of devel-
oping MS. Multiple sclerosis is not an inherited disease and 
does not occur from generation to generation. These obser-
vations indicate that the genetic factor is of great im-
portance for the development of MS, however, the devel-
opment of the disease also requires the participation of oth-
er factors influencing the body before the adult age [1,2]. 
The diet and fatty acid content may have an impact here 
(found in vegetable fats, acids may have a protective func-
tion against MS). The development of the disease may be 
favored by increased concentration of heavy metals and 
increased temperature that may deteriorate nerve conduc-
tion, increasing the risk of developing or exacerbating 
symptoms. [23-28] The peat composition of soils, the pre-
dominance of coniferous forests, poor quality of drinking 
water from old water installations and home wells as well 
as the possible adverse effects of the wood processing in-
dustry can also be important for the risk of developing the 
disease [16,29]. 
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